A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Cu(II) ATSM (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Collaborative Medicinal Development
- 14 Oct 2019 According to a Collaborative Medicinal Development media release, the first patient has been enrolled in the study.
- 14 Oct 2019 Status changed from not yet recruiting to recruiting, according to a Collaborative Medicinal Development media release.
- 06 Sep 2019 Status changed from planning to not yet recruiting.